STATEMENT OF ANTHONY S. FAUCI, M.D., DIRECTOR, MARGARET JOHNSTON, PH.D., ASSISTANT DIRECTOR FOR HIV/AIDS VACCINES, AND GARY J. NABEL, M.D. PH.D., DIRECTOR, VACCINE RESEARCH CENTER, NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES NATIONAL INSTITUTES

[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

 



U.S. Department of Health and Human Services 
NATIONAL INSTITUTES OF HEALTH 
NIH News 
National Institute of Allergy and Infectious Diseases (NIAID)
http://www3.niaid.nih.gov/

FOR IMMEDIATE RELEASE: Monday, May 15, 2006

CONTACT: NIAID News and Public Information Branch, 301-402-1663,
niaidnews@xxxxxxxxxxxxx 

STATEMENT OF ANTHONY S. FAUCI, M.D., DIRECTOR, MARGARET JOHNSTON, PH.D.,
ASSISTANT DIRECTOR FOR HIV/AIDS VACCINES, AND GARY J. NABEL, M.D. PH.D.,
DIRECTOR, VACCINE RESEARCH CENTER, NATIONAL INSTITUTE OF ALLERGY AND
INFECTIOUS DISEASES NATIONAL INSTITUTES OF HEALTH ON HIV VACCINE
AWARENESS DAY MAY 18, 2006

The 9th annual HIV Vaccine Awareness Day on May 18, 2006, serves as a
somber reminder of the more than 25 million people who have died of AIDS
since the first cases were reported nearly 25 years ago. Although
research advances have greatly extended the life expectancy of a person
infected with HIV today, there is no cure for HIV/AIDS. The 14,000 new
HIV infections that occur in the world every day underscore the urgent
need for a safe and effective vaccine to prevent HIV infection.

Basic research has helped us understand how HIV causes AIDS and how the
immune system attempts to contain infection. This knowledge has
catalyzed significant progress in the development of vaccines for HIV.
Since 1987, dedicated investigators supported by the National Institute
of Allergy and Infectious Diseases (NIAID) have enrolled more than
23,000 volunteers in 96 HIV vaccine clinical trials that have tested at
least 58 different vaccine candidates.

However, an effective vaccine eludes us. We must continue to accelerate
efforts in both basic and clinical research to design promising new
vaccine candidates and to test their potential for preventing HIV
infection. Such research efforts are progressing with a renewed spirit
of domestic and international cooperation. Examples of new collaborative
initiatives include the Global HIV/AIDS Vaccine Enterprise, an alliance
of independent organizations around the world dedicated to accelerating
the development of a preventive HIV vaccine; the Center for HIV-AIDS
Vaccine Immunology (CHAVI), a consortium of universities and academic
medical centers with the goal of solving major problems in HIV vaccine
design and development; and the Partnership for AIDS Vaccine Evaluation
(PAVE), a voluntary consortium of U.S. government agencies and key U.S.
government-funded organizations involved in the development and
evaluation of preventive HIV/AIDS vaccines, including the conduct of HIV
vaccine clinical trials. In addition, working in close partnership with
these groups, the NIAID Vaccine Research Center continues its efforts to
develop novel vaccine candidates and to evaluate their potential for
inducing protective immunity.

Local communities also have joined the effort to develop and test HIV
vaccines. As part of NIAID's HIV Vaccine Communications Campaign, 20
community-based organizations across the U.S. are working to educate
their communities about HIV vaccine research. These organizations work
hand-in-hand with the NIAID-sponsored HIV Vaccine Trials Network to
ensure that their communities are informed and involved in the many
aspects of clinical research. The need for volunteers to participate
directly in clinical research trials, to provide input for the research
process, to educate local communities and to bolster support for HIV
vaccine research has never been greater.

Today, we acknowledge and thank the thousands of volunteers, community
members, health professionals and scientists who conduct and participate
in HIV vaccine research. We sincerely appreciate their selfless
contributions to the global effort to find a vaccine for HIV.

On May 18, show your support for HIV vaccine research by wearing your
AIDS ribbon upside-down to symbolize a "V" for vaccines. Please take
this opportunity to learn more about HIV vaccine research and to educate
someone you know about the importance of developing a vaccine for HIV.

For more information about HIV Vaccine Awareness Day, vaccine research
or HIV Vaccine Awareness Day events at the local level, visit
http://www3.niaid.nih.gov/news/events/HVAD/ or call 1-800-HIV-0440
(bilingual English/Spanish).

Dr. Fauci is the director of the National Institute of Allergy and
Infectious Diseases (NIAID) at the National Institutes of Health in
Bethesda, Maryland. Dr. Johnston is assistant director for HIV/AIDS
vaccines at NIAID and director of the Vaccine and Prevention Research
Branch of the Division of AIDS within NIAID. Dr. Nabel is the director
of the Dale and Betty Bumpers Vaccine Research Center of NIAID.

The HIV Vaccine Communications Campaign, an initiative of the Division
of AIDS, aims to create an environment in which HIV affected communities
and individuals are more aware, educated and supportive of HIV vaccine
research and have more positive attitudes towards clinical trial
volunteerism. This year's campaign makes broad comparisons between other
great causes and the search to end the HIV/AIDS pandemic through the
discovery of a preventive HIV vaccine. The campaign invites the public
to "Be the Generation" that ends AIDS by learning more about the search
for an HIV vaccine. This new Web site was created to provide the public
with a single source of information about the campaign and preventive
HIV vaccine research.

Learn more about the Campaign and preventive HIV vaccine research by
visiting the Web site, www.bethegeneration.org.

Media inquiries can be directed to the NIAID News Office at
301-402-1663, niaidnews@xxxxxxxxxxxxxx

NIAID is a component of the National Institutes of Health. NIAID
supports basic and applied research to prevent, diagnose and treat
infectious diseases such as HIV/AIDS and other sexually transmitted
infections, influenza, tuberculosis, malaria and illness from potential
agents of bioterrorism. NIAID also supports research on basic
immunology, transplantation and immune-related disorders, including
autoimmune diseases, asthma and allergies.

The National Institutes of Health (NIH) -- "The Nation's Medical
Research Agency" -- includes 27 Institutes and Centers and is a
component of the U.S. Department of Health and Human Services. It is the
primary federal agency for conducting and supporting basic, clinical and
translational medical research, and it investigates the causes,
treatments, and cures for both common and rare diseases. For more
information about NIH and its programs, visit www.nih.gov.
  
##
 
This NIH News Release is available online at:
http://www.nih.gov/news/pr/may2006/niaid-15.htm.

To subscribe (or unsubscribe) from this list, go to
http://list.nih.gov/cgi-bin/wa?SUBED1=nihpress&A=1.

[Index of Archives]     [CDC News]     [FDA News]     [USDA News]     [Yosemite News]     [Steve's Art]     [PhotoForum]     [SB Lupus]     [STB]

  Powered by Linux